<DOC>
	<DOCNO>NCT00273338</DOCNO>
	<brief_summary>The primary objective study : - To evaluate effect DN-101 combination docetaxel ( ASCENT regimen ) survival metastatic androgen-independent prostate cancer The secondary objective study : - To determine effect ASCENT regimen rate thromboembolic event ( blood clot ) - To determine effect ASCENT regimen prevention skeletal-related event ( fracture ) - A Separate sub-study conduct select study site North America determine population PK DN-101 .</brief_summary>
	<brief_title>DN-101 Combination With Docetaxel Androgen-Independent Prostate Cancer ( AIPC ) ( AIPC Study Calcitriol Enhancing Taxotere ASCENT-2 )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Histopathologically cytologically proven adenocarcinoma prostate Documented metastatic prostate adenocarcinoma Documented progression androgen ablation therapy detect rise prostate specific antigen ( PSA ) and/or image Age &gt; = 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; = 2 Adequate hematologic , renal hepatic function Life expectancy &gt; = 3 month Prior chemotherapy , except estramustine Prior chemotherapy docetaxel Prior isotope therapy ( e.g. , strontium89 , samarium153 , etc . ) One contraindication use corticosteroid History cancerrelated hypercalcemia</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Androgen-independent Prostate Cancer ( AIPC )</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>DN-101</keyword>
	<keyword>calcitriol</keyword>
	<keyword>Taxotere</keyword>
	<keyword>docetaxel</keyword>
</DOC>